Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital, Organ Transplantation Research Center of Guangdong Province, Organ Transplantation Institute, Sun Yat-sen University, Guangzhou, China.
Guangdong Key Laboratory of Liver Disease Research, Key Laboratory of Liver Disease Biotherapy and Translational Medicine, Guangdong Higher Education Institutes, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
FASEB J. 2019 Feb;33(2):1695-1710. doi: 10.1096/fj.201800131RR. Epub 2018 Sep 18.
Mesenchymal stem cells (MSCs) have been reported to exert therapeutic effects on immunoregulation, tissue repair, and regeneration from the bench to the bedside. Increasing evidence demonstrates that extracellular vesicles (EVs) derived from MSCs could contribute to these effects and are considered as a potential replacement for stem cell-based therapies. However, the efficacy and underlying mechanisms of EV-based treatment in hepatic ischemia-reperfusion injury (IRI) remain unclear. Here, we demonstrated that human umbilical cord MSC-EVs (huc-MSC-EVs) could protect against IRI-induced hepatic apoptosis by reducing the infiltration of neutrophils and alleviating oxidative stress in hepatic tissue in vivo. Meanwhile, huc-MSC-EVs reduced the respiratory burst of neutrophils and prevented hepatocytes from oxidative stress-induced cell death in vitro. Interestingly, we found that the mitochondria-located antioxidant enzyme, manganese superoxide dismutase (MnSOD), was encapsulated in huc-MSC-EVs and reduced oxidative stress in the hepatic IRI model. Knockdown of MnSOD in huc-MSCs decreased the level of MnSOD in huc-MSC-EVs and attenuated the antiapoptotic and antioxidant capacities of huc-MSC-EVs, which could be partially rescued by MnSOD mimetic manganese (III) 5,10,15,20-tetrakis (4-benzoic acid) porphyrin (MnTBAP). In summary, these findings provide new clues to reveal the therapeutic effects of huc-MSC-EVs on hepatic IRI and evaluate their preclinical application.-Yao, J., Zheng, J., Cai, J., Zeng, K., Zhou, C., Zhang, J., Li, S., Li, H., Chen, L., He, L., Chen, H., Fu, H., Zhang, Q., Chen, G., Yang, Y., Zhang, Y. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate rat hepatic ischemia-reperfusion injury by suppressing oxidative stress and neutrophil inflammatory response.
间充质干细胞 (MSCs) 已被报道在免疫调节、组织修复和再生方面具有治疗作用,从实验室到临床。越来越多的证据表明,MSC 来源的细胞外囊泡 (EVs) 可能有助于这些作用,并被认为是基于干细胞治疗的潜在替代品。然而,EV 基于治疗在肝缺血再灌注损伤 (IRI) 中的疗效和潜在机制尚不清楚。在这里,我们证明人脐带 MSC-EVs (huc-MSC-EVs) 可以通过减少中性粒细胞的浸润和减轻肝组织中的氧化应激来保护 IRI 诱导的肝细胞凋亡。同时,huc-MSC-EVs 减少了中性粒细胞的呼吸爆发,并防止肝细胞受到氧化应激诱导的细胞死亡。有趣的是,我们发现位于线粒体的抗氧化酶锰超氧化物歧化酶 (MnSOD) 被包裹在 huc-MSC-EVs 中,并减轻了肝 IRI 模型中的氧化应激。在 huc-MSCs 中敲低 MnSOD 会降低 huc-MSC-EVs 中的 MnSOD 水平,并减弱 huc-MSC-EVs 的抗凋亡和抗氧化能力,MnSOD 模拟物锰 (III) 5,10,15,20-四 (4- 苯甲酸) 卟啉 (MnTBAP) 可部分挽救。总之,这些发现为揭示 huc-MSC-EVs 对肝 IRI 的治疗作用提供了新的线索,并评估了它们的临床前应用。-姚,J.,郑,J.,蔡,J.,曾,K.,周,C.,张,J.,李,S.,李,H.,陈,L.,何,L.,陈,H.,傅,H.,张,Q.,陈,G.,杨,Y.,张,Y. 人脐带间充质干细胞衍生的细胞外囊泡通过抑制氧化应激和中性粒细胞炎症反应减轻大鼠肝缺血再灌注损伤。